CAM
ABMD

Claret Asset Management’s Abiomed Inc ABMD Stock Holding History

Claret Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-563
Closed -$230K – 231
2018
Q2 		$230K Buy
+563
New +$204K 0.05% 172

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Claret Asset Management's ABMD Position: Q3 2018 in Review

Claret Asset Management sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 563 shares — an estimated $230K sold.

Claret Asset Management first reported a position in ABMD in Q2 2018 and held it in 1 quarter. The position peaked at $230K in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • Claret Asset Management reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
  • Claret Asset Management sold 563 Abiomed Inc shares in Q3 2018, an estimated $230K.
  • Claret Asset Management first reported a position in Abiomed Inc in Q2 2018 and held it in 1 quarter.
  • Claret Asset Management's Abiomed Inc position peaked at $230K in Q2 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Claret Asset Management's 13F filing for Q3 2018, filed 30 Oct 2018.